The mechanisms for the different proarrhythmic potential of antiarrhythmic drugs in the presence of comparable QT prolongation are not completely understood. The reasons for the lower proarrhythmic potential of amiodarone as compared with other class-III antiarrhythmic drugs such as sotalol, a fact that has been well established for years, is insufficiently known. Therefore, the aim of our study was to assess the different electrophysiologic effects of amiodarone and sotalol in a previously developed experimental model of proarrhythmia. In eight male rabbits, amiodarone (280-340 mg/d) was fed over a period of six weeks. Hearts were excised and retrogradely perfused. Up to eight simultaneous epi- and endocardial monophasic action potentials (MAP) were recorded. Results were compared with sotalol-treated (10-50-100 microM) hearts (n = 13). Amiodarone and sotalol (50 microM and 100 microM) led to a significant increase in QT interval (mean increase: amiodarone: 31 +/- 6 ms; sotalol: 41 +/- 4 ms and 61 +/- 9 ms) and MAP-duration (mean increase-MAP90: amiodarone: 20 +/- 5 ms; sotalol: 17 +/- 5 ms and 25 +/- 8 ms) (P < 0.01). In bradycardic (AV-blocked) hearts, MAP-recordings demonstrated reverse-use dependence and a significant increase in dispersion of repolarization (MAP90) in the presence of sotalol (P < 0.01), but not in amiodarone-treated hearts (10%; p = ns). Sotalol led to early afterdepolarizations (EAD) and torsade de pointes (TdP) after lowering of potassium concentration (6 of 13 hearts). In amiodarone-treated, hypokalemic hearts, no EAD or TdP occurred. Sotalol changed the MAP configuration to a triangular pattern (ratio-MAP90/50: 1.52 as compared with 1.36 at baseline) whereas amiodarone caused a rectangular pattern of MAP prolongation (ratio-MAP90/50: 1.36). In conclusion, these results show no direct correlation between the occurrence of TdP and the degree of QT prolongation. Several factors including reverse-use dependence, dispersion of repolarization, and the propensity to induce early afterdepolarizations but also differences in the action potential configuration may help to understand proarrhythmic side effects of drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.fjc.0000129581.81508.78 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.
N Engl J Med
November 2024
From the QEII Health Sciences Centre, Dalhousie University, Halifax, NS (J.L.S., R.P., A.A.), Western University, London, ON (A.S.L.T., L.J.G.), the Population Health Research Institute (J.S.H.) and Hamilton Health Sciences Centre (G.A.), Hamilton, ON, the University of Ottawa Heart Institute (G.M.N., P.B.N.), the McGill University Health Centre (V.E.), the Montreal Heart Institute (L.R., K.D.), and Centre Hospitalier de l'Universitaire de Montreal (J.-M.R.), Montreal, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC (J.-F.R.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec (J.-F.S., I.N.), the University of British Columbia, Vancouver (M.D.), Kelowna General Hospital, Kelowna, BC (C.L.), the University of Ottawa, Ottawa (G.A.W.), and the University of Calgary, Calgary, AB (V.K., S.W.) - all in Canada; Vanderbilt University Medical Center, Nashville (W.G.S., A.K.); Centre Hospitalier Universitaire de Bordeaux, L'institut des Maladies du Rythme Cardiaque, Bordeaux (F.S.), and Centre Hospitalier Universitaire de Nancy, Nancy (C.C.) - both in France; and St. Mary's General Hospital, Passaic, NJ (U.J.).
Background: Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular tachycardia. Whether catheter ablation is more effective than antiarrhythmic drugs as a first-line therapy in patients with ventricular tachycardia is uncertain.
View Article and Find Full Text PDFBackground: This study investigated drug-drug interactions in patients with atrial fibrillation taking both a direct oral anticoagulant (DOAC) and an antiarrhythmic drug.
Methods And Results: Using data from the National Health Insurance database (2012-2018), we identified 78 805 patients with atrial fibrillation on DOACs, with 24 142 taking amiodarone, 8631 taking propafenone, 2784 taking dronedarone, 297 taking flecainide, 177 taking sotalol, and 42 772 on DOACs alone. Patients with bradycardia, heart block, heart failure, mitral stenosis, prosthetic valves, or incomplete data were excluded.
Clinical, electrocardiographic, and diagnostic imaging features and outcomes in cats with electrocardiographic diagnosis of ventricular pre-excitation: a retrospective study of 23 cases (2010-2022).
J Vet Cardiol
December 2024
MedVet Cincinnati, 3964 Red Bank Road, Fairfax, OH 45227, USA.
Article Synopsis
- The study focuses on ventricular pre-excitation (VPE) in cats, which occurs when abnormal electrical pathways cause premature ventricle excitation, leading to a specific type of rapid heart rate known as orthodromic atrioventricular reciprocating tachycardia (SVT).
- The research analyzed 23 cats diagnosed with VPE from 2010 to 2022, reviewing their clinical signs, ECG results, treatments, and outcomes.
- Results showed that most cats experienced symptoms like collapse and respiratory distress, and the median survival time after diagnosis was a favorable 5.1 years, indicating a generally good prognosis for affected cats.
Long QT Syndrome With Drugs Used in the Management of Arrhythmias: A Systematic Review.
Cureus
July 2024
General Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Long QT syndrome (LQTS) is a severe cardiac disorder characterized by an abnormally prolonged QTc interval on an electrocardiogram (ECG), which can result in life-threatening irregular heart rhythms. The use of certain medications, particularly anti-arrhythmic drugs such as quinidine, sotalol, and amiodarone, can lead to acquired LQTS by prolonging the QT interval through the inhibition of specific ion channels responsible for heart repolarization, which may present symptoms like fainting, seizures, and sudden cardiac arrest. This systematic review, conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, focused on analyzing the association between Long QT syndrome and drugs utilized for managing arrhythmias, involving a thorough examination of six selected studies from an initial pool of 68 articles.
View Article and Find Full Text PDFEffect of Obesity on the Use of Antiarrhythmics in Adults With Atrial Fibrillation: A Narrative Review.
Clin Cardiol
August 2024
Centre for Chronic & Complex Care Research, Blacktown Hospital, Western Sydney Local Health District, Blacktown, New South Wales, Australia.
Background: Atrial fibrillation (AF) and obesity coexist in approximately 37.6 million and 650 million people globally, respectively. The anatomical and physiological changes in individuals with obesity may influence the pharmacokinetic properties of drugs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!